Lisen Imprinting Diagnostics
Biotechnology ResearchDelaware, United States2-10 Employees
LisenID is focused on the elimination of indeterminate cancer diagnoses. Utilizing epigenetic imprinting biomarkers and AI, we have developed a molecular test & machine learning platform to visually identify carcinogenesis at onset in routine tumor biopsy samples and predict cancer risk with up to 95% accuracy. With the potential to scale to 13 different cancer types and applicable in screening and diagnosis, our solutions equip clinicians and pathologists to make the best decisions for our patients--as early as possible.
1-888-653-2347 
support@leadiq.com 
